Nearly one-third of stage III colorectal cancer patients relapse despite completing standard adjuvant chemotherapy — a stubborn failure rate that has driven urgent interest in biomarkers capable of identifying who actually benefits from treatment. New RNA-sequencing data from tumor tissue may offer two unexpected predictive signals: a common gut pathogen and the diversity of a patient's own immune receptor repertoire.
Analyzing tumor specimens from 253 surgically treated stage III colorectal cancer patients — 118 of whom received adjuvant chemotherapy — researchers performed comprehensive RNA sequencing that captured transcriptional subtypes, intratumoral microbiome composition, immune cell fractions, and T-cell receptor (TCR) diversity. Among patients receiving chemotherapy, two independent predictors of recurrence-free survival emerged in multivariable modeling. High intratumoral abundance of Fusobacterium was associated with nearly a fourfold increase in recurrence risk (hazard ratio 3.95), while greater diversity of TCR alpha-delta (TRAD) chains was associated with a roughly 60% reduction in recurrence risk (hazard ratio 0.41). Notably, Fusobacterium-detectable tumors appeared in 97.6% of the cohort, suggesting its abundance rather than mere presence is the critical variable.
Fusobacterium nucleatum has emerged over the past decade as one of colorectal cancer's most studied microbial co-conspirators, linked to tumor progression, immune evasion, and chemotherapy resistance through mechanisms including TLR4 activation and autophagy induction. What makes this analysis distinctive is pairing that bacterial signal with adaptive immune architecture — specifically the less-studied alpha-delta TCR compartment, which bridges innate-like and conventional T-cell responses at mucosal surfaces. The co-occurrence of a hostile microbial environment and a depleted immune receptor pool may reflect compounding immune suppression. Key limitations include the retrospective single-institution design, modest cohort size, and the 22-year enrollment window spanning treatment-era heterogeneity. Replication in prospective multicenter cohorts is essential before these biomarkers inform clinical triage. Still, the mechanistic plausibility and effect sizes here position this as a genuinely promising — if preliminary — framework for personalizing adjuvant therapy decisions.